Amicus Therapeutics Inc. (FOLD) Financial Statements (2024 and earlier)

Company Profile

Business Address 3675 MARKET STREET
PHILADELPHIA, PA 19104
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments286,200293,595482,496483,269452,740504,152
Cash and cash equivalents246,994148,813245,197163,240142,83779,749
Short-term investments39,206144,782237,299320,029309,903424,403
Receivables87,63266,19652,67246,92333,28421,962
Inventory, net of allowances, customer advances and progress billings59,69623,81626,81819,55614,0418,390
Inventory59,69623,81626,81819,55614,0418,390
Other undisclosed current assets49,53340,20934,84829,72120,00816,592
Total current assets:483,061423,816596,834579,469520,073551,096
Noncurrent Assets
Operating lease, right-of-use asset26,31229,53420,58623,29633,315
Property, plant and equipment31,66730,77842,49643,86347,70511,375
Intangible assets, net (including goodwill)218,287220,797220,797220,797220,797220,797
Goodwill197,797197,797197,797197,797197,797197,797
Intangible assets, net (excluding goodwill)20,49023,00023,00023,00023,00023,000
Other noncurrent assets18,55319,24224,42719,09528,3176,683
Total noncurrent assets:294,819300,351308,306307,051330,134238,855
TOTAL ASSETS:777,880724,167905,140886,520850,207789,951
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:144,24593,63698,15396,841120,37380,625
Interest and dividends payable  3,6794,189
Taxes payable6,15411,1777,300 
Employee-related liabilities24,25823,02527,15621,731
Accounts payable15,12015,41321,51317,06321,7226,606
Accrued liabilities 86,06853,00518,09712,84415,80010,797
Other undisclosed accounts payable and accrued liabilities 43,05725,21828,13132,73244,71637,302
Debt     7,189 
Business combination, contingent consideration, liability  21,41718,9008,900  
Other undisclosed current liabilities23,44423,96528,92223,9351,2505,500
Total current liabilities:167,689139,018145,975129,676128,81286,125
Noncurrent Liabilities
Long-term debt and lease obligation   43,36345,604203,036321,740
Long-term debt, excluding current maturities     149,505321,740
Liabilities, other than long-term debt62,15965,45613,17028,20033,02822,553
Deferred income tax liabilities  4,9394,9304,8965,051
Other liabilities13,2828,9396,8016,3795,2962,853
Operating lease, liability48,87751,57843,36345,60453,531
Business combination, contingent consideration, liability   1,43916,92522,68119,700
Other undisclosed noncurrent liabilities387,858396,646395,263396,6608,90616,621
Total noncurrent liabilities:450,017462,102451,796470,464244,970360,914
Total liabilities:617,706601,120597,771600,140373,782447,039
Equity
Equity, attributable to parent160,174123,047307,369286,380476,425342,912
Common stock2,9182,8152,8082,6502,5981,942
Additional paid in capital2,836,0182,664,7442,595,4192,308,5782,227,2251,740,061
Accumulated other comprehensive income (loss)5,241(12,105)4,9818,2272,82568
Accumulated deficit(2,684,074)(2,532,490)(2,295,922)(2,045,462)(1,768,610)(1,412,222)
Warrants and rights outstanding71838312,38712,38713,063
Total equity:160,174123,047307,369286,380476,425342,912
TOTAL LIABILITIES AND EQUITY:777,880724,167905,140886,520850,207789,951

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues399,356329,233305,514260,886182,23791,245
Cost of revenue
(Cost of Goods and Services Sold)
(37,326)(38,599)(34,466)(31,044)(21,963)(14,404)
Gross profit:362,030290,634271,048229,842160,27476,841
Operating expenses(439,241)(502,754)(477,482)(476,840)(464,311)(405,618)
Operating loss:(77,211)(212,120)(206,434)(246,998)(304,037)(328,777)
Nonoperating income (expense)(8,808)7,200(2,392)2,4457,6232,090
Investment income, nonoperating7,0783,0245093,22610,24910,461
Loss, foreign currency transaction, before tax      (2,739)
Other nonoperating income (expense)(15,886)4,176(2,901)(781)(2,626)(5,632)
Interest and debt expense(64,082)(37,119)(32,728)(29,701)(59,496)(22,402)
Loss from continuing operations before income taxes:(150,101)(242,039)(241,554)(274,254)(355,910)(349,089)
Income tax expense (benefit)(1,483)5,471(8,906)(2,598)(478)94
Loss from continuing operations:(151,584)(236,568)(250,460)(276,852)(356,388)(348,995)
Loss before gain (loss) on sale of properties:(250,460)(276,852)(356,388)(348,995)
Net loss available to common stockholders, diluted:(151,584)(236,568)(250,460)(276,852)(356,388)(348,995)

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net loss:(151,584)(236,568)(250,460)(276,852)(356,388)(348,995)
Other comprehensive income (loss)    50(182) 
Comprehensive loss:(151,584)(236,568)(250,460)(276,802)(356,570)(348,995)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent17,346(17,086)(3,246)5,3522,9392,546
Comprehensive loss, net of tax, attributable to parent:(134,238)(253,654)(253,706)(271,450)(353,631)(346,449)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: